Mirum Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (MIRM)

Historical Holders from Q3 2019 to Q3 2025

Symbol
MIRM on Nasdaq
CUSIP
604749101
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
49.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
56.9M
Holdings value
$4.17B
% of all portfolios
0.007%
Grand Portfolio weight change
+0%
Number of holders
263
Number of buys
159
Number of sells
-89
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (MIRM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10% -5.45% $366M -$17.5M 5M -4.56% JANUS HENDERSON GROUP PLC Sep 30, 2025
Frazier Life Sciences IX, L.P. 7.4% 0% $274M 3.74M 0% James N. Topper Nov 1, 2025
EVENTIDE ASSET MANAGEMENT, LLC 5.43% $103M 2.61M Eventide Asset Management, LLC Dec 31, 2024
BIOTECHNOLOGY VALUE FUND L P 3% $110M 1.5M BVF PARTNERS L P/IL Sep 30, 2025

Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (MIRM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 56.9M $4.17B +$135M $73.31 263
2025 Q2 55.4M $2.82B +$70.4M $50.89 212
2025 Q1 54.1M $2.44B +$49.1M $45.05 213
2024 Q4 53M $2.19B -$15.3M $41.35 204
2024 Q3 53.1M $2.07B -$12.7M $39.00 178
2024 Q2 53.4M $1.82B +$11.9M $34.19 160
2024 Q1 53.2M $1.34B +$67.5M $25.12 169
2023 Q4 253K $7.49M -$2.05M $29.52 3
2023 Q3 48.7M $1.54B +$387M $31.60 157
2023 Q2 36.9M $956M +$63.1M $25.87 143
2023 Q1 34.7M $833M +$34M $24.02 114
2022 Q4 33.3M $650M -$11.8M $19.50 101
2022 Q3 32M $672M +$84.2M $21.01 105
2022 Q2 29.1M $565M +$45.7M $19.46 100
2022 Q1 26.8M $590M +$50.8M $22.02 98
2021 Q4 24.8M $395M +$18.7M $15.95 80
2021 Q3 21.4M $426M +$2.76M $19.92 69
2021 Q2 21.5M $371M +$679K $17.29 65
2021 Q1 23.4M $425M -$8.43M $19.82 61
2020 Q4 22M $384M +$52.3M $17.46 71
2020 Q3 18.7M $361M -$1.29M $19.27 50
2020 Q2 18.8M $366M +$8.88M $19.46 56
2020 Q1 18.6M $260M +$32.1M $14.00 43
2019 Q4 16.2M $398M +$12.8M $24.52 39
2019 Q3 16.5M $166M +$166M $10.06 37